Literature DB >> 11438300

Comparative actions of insulin sensitizers on ion channels in vascular smooth muscle.

K Eto1, Y Ohya, Y Nakamura, I Abe, M Fujishima.   

Abstract

Thiazolidinedione and isoxazolidinedione insulin sensitizers activate peroxisome proliferator-activated receptor gamma (PPAR gamma). Some thiazolidinediones modify ion channels in smooth muscles; however, the mechanism by which their actions occur has not been clarified. We, thus, examined the effects of three thiazolidinediones (troglitazone, pioglitazone, and rosiglitazone) and isoxazolidinedione (JTT-501), as well as an intrinsic ligand for PPAR gamma, 15-deoxy-Delta(12,14) prostaglandin J(2) (prostaglandin J(2)), on voltage-operated Ca(2+) currents (I(Ca)), voltage-dependent K(+) currents (I(Kv)), and Ca(2+)-activated K(+) currents (I(Kca)), to clarify whether a thiazolidinedione structure or PPAR gamma activation is related to their actions on ion channels. The whole-cell patch clamp method was used to record currents in smooth muscle cells from guinea-pig mesenteric arteries. Thiazolidinediones inhibited I(Ca) in a dose-dependent manner (troglitazone>pioglitazone=rosiglitazone). Troglitazone (> or =1 microM) and rosiglitazone (100 microM), but not pioglitazone, inhibited I(Kv). Rosiglitazone (> or =10 microM) enhanced, troglitazone (> or =1 microM) inhibited, and pioglitazone did not affect I(Kca). A high concentration of JTT-501 (100 microM) inhibited I(Ca), I(Kv), and I(Kca) to a similar extent. Prostaglandin J(2) enhanced I(Kca), but affected neither I(Ca) nor I(Kv). In summary, the three thiazolidinediones and isoxazolidinedione act differently on Ca(2+) and K(+) channels in vascular smooth muscle. The action of thiazolidinediones on I(Ca) could be attributed to specific regions of the molecules and not to activation of PPAR gamma. Involvement of PPAR gamma activation in the stimulation of I(Kca) is possible but should be tested further.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11438300     DOI: 10.1016/s0014-2999(01)01047-0

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  18 in total

1.  Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone.

Authors:  Hye Sook Ahn; Sung Eun Kim; Hyun-Jong Jang; Myung-Jun Kim; Duck-Joo Rhie; Shin-Hee Yoon; Yang-Hyeok Jo; Myung-Suk Kim; Ki-Wug Sung; Seong Yun Kim; Sang June Hahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-11-21       Impact factor: 3.000

2.  Whole-cell recordings of calcium and potassium currents in acutely isolated smooth muscle cells.

Authors:  Qing Cai; Zhong-Liang Zhu; Xiao-Li Fan
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

3.  Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

Authors:  Lei Yu; Xin Jin; Yang Yang; Ningren Cui; Chun Jiang
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

4.  Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

Authors:  Lei Yu; Xin Jin; Ningren Cui; Yang Wu; Zhenda Shi; Daling Zhu; Chun Jiang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

5.  Chemical proteomics-based analysis of off-target binding profiles for rosiglitazone and pioglitazone: clues for assessing potential for cardiotoxicity.

Authors:  Brian R Hoffmann; Mohamed F El-Mansy; Daniel S Sem; Andrew S Greene
Journal:  J Med Chem       Date:  2012-09-28       Impact factor: 7.446

6.  High salt diet modulates vascular response in A2AAR (+/+) and A 2AAR (-/-) mice: role of sEH, PPARγ, and K ATP channels.

Authors:  Isha Pradhan; Catherine Ledent; S Jamal Mustafa; Christophe Morisseau; Mohammed A Nayeem
Journal:  Mol Cell Biochem       Date:  2015-03-05       Impact factor: 3.396

7.  Rapid and contrasting effects of rosiglitazone on transient receptor potential TRPM3 and TRPC5 channels.

Authors:  Yasser Majeed; Yahya Bahnasi; Victoria A L Seymour; Lesley A Wilson; Carol J Milligan; Anil K Agarwal; Piruthivi Sukumar; Jacqueline Naylor; David J Beech
Journal:  Mol Pharmacol       Date:  2011-03-15       Impact factor: 4.436

8.  Effects of rosiglitazone on altered electrical left ventricular papillary muscle activities of diabetic rat.

Authors:  Servet Kavak; Mustafa Emre; Tamer Tetiker; Tuyana Kavak; Zekeriya Kolcu; Ismail Günay
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-21       Impact factor: 3.000

9.  Effects of chronic PPAR-agonist treatment on cardiac structure and function, blood pressure, and kidney in healthy sprague-dawley rats.

Authors:  Eileen R Blasi; Jonathan Heyen; Michelle Hemkens; Aileen McHarg; Carolyn M Ecelbarger; Swasti Tiwari
Journal:  PPAR Res       Date:  2009-06-11       Impact factor: 4.964

10.  Association of urinary bisphenol a concentration with heart disease: evidence from NHANES 2003/06.

Authors:  David Melzer; Neil E Rice; Ceri Lewis; William E Henley; Tamara S Galloway
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.